These differences remained when the gross tumor volume was considered. Our goal is the best way to found to treat the cancer without further weakening the patient, said Ritsuko Komaki, about 114,000 MD Anderson Department of Radiation Oncology and lead author of the study. Standard care currently provides a 25 % five-year survival rate, but as a physician I have seen how the treatment of the patients affects the general health. Are they tired, suffering from night sweats, are more susceptible to infection and have to compromise their treatment. With proton therapy, we can now have the option to reduce this toxicity so that treatment dosage can be maximized. .. Researchers compared bone marrow toxicity levels in 142 patients for lung cancer between January 2003 and June 2008 treated.
###Besides Komaki and Cox, include MD Anderson researchers contributing to this study Samir V. Xiong Wei MD, Pamela Allen Ph. Richard Amos M. Radhe Mohan, Chang MD, Zhongxing Liao, and Lei Dong, of the Department of Radiation Oncology, radiation Physics and Biostatistics and Applied Mathematics. News and World Reportnce, Cox his study of proton beam therapy and its effect on tissue toxicity.Said Tomas Leanderson, President & CEO of Active Biotech.. Active Biotech AB and Ipsen today announced that in of wider partnerships to co-develop and market Active Biotech investigational Tasquinimod ‘TASQ ‘registered. The global period III clinical trial of TASQ in men metastatic castration -resistant prostate cancer was recent Active Biotech Active Biotech being and recruitment of patients in progress. Marc de Garidel, Chairman and CEO Officer of Ipsen said: ‘This new partnership will subject our of our uro-oncology franchises , the success ongoing Phase III clinical trial trial for the treatment in metastatic castrating – resistant to. Prostate and following marketing approval TASQ receive a perfect adapt into our current portfolio, addition to the sustained-release formulations Decapepty.
To perform and financing a Europe a supporting study patients with prostate cancer from R and D budgets. Any costs of TASQ into future more cancer indications in development shared.